Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06836518

Sialic Acid in Hepatocellular Carcinoma

Sponsor: Sohag University

View on ClinicalTrials.gov

Summary

Hepatocellular carcinoma (HCC) accounts for approximately 90% of the cases of liver cancer and is associated with high morbidity and mortality. The increased sialic acids(SAs) in tumor cells are mainly caused by the special metabolic flux and aberrant expression of sialyltransferases/sialidases, The high sensitivity of sialic acids in or plasma as a tumor marker has been reported in various cancerous conditions the level of sialic acid(SA) activity was found to offer highly specific and sensitive tumor biomarker for diagnosis and follow up of HCC post-therapy.

Official title: Serum Sialic Acid as a Novel Biomarker in the Diagnosis of Hepatocellular Carcinoma

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

OBSERVATIONAL

Enrollment

100

Start Date

2025-03-01

Completion Date

2026-05-01

Last Updated

2025-02-20

Healthy Volunteers

Not specified

Interventions

DIAGNOSTIC_TEST

serum sialic acid

measurement of serum sialic acid to evaluate its efficacy in the diagnosis of hepatocellular carcinoma